Valuation: Cosmo Pharmaceuticals S.p.A

Market Cap 1.11B 1.27B 1.03B 947M 1.79B 122B 1.82B 12.16B 4.77B 60.58B 4.79B 4.68B 203B P/E 2026 *
959x
P/E 2027 * 22.3x
Enterprise Value 1.08B 1.24B 1B 923M 1.74B 119B 1.77B 11.85B 4.65B 59.02B 4.66B 4.56B 198B EV / Sales 2026 *
10.2x
EV / Sales 2027 * 6.13x
Free-Float
40.52%
Yield 2026 *
3.3%
Yield 2027 * 3.5%

Last Transcript: Cosmo Pharmaceuticals S.p.A

Manager TitleAgeSince
Chief Executive Officer 52 24/05/2024
Director of Finance/CFO - 11/11/2024
Chief Tech/Sci/R&D Officer 53 01/01/2009
Director TitleAgeSince
Chairman 71 01/01/2014
Director/Board Member 71 01/04/2012
Director/Board Member 54 24/05/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-3.95%+55.23%+152.74% 1,024B
+0.21%-2.68%+55.61%+53.02% 618B
-2.51%-3.25%+32.76%+67.76% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.14%-0.24%+34.41%+39.01% 297B
-0.69%-0.30%+11.55%+12.93% 264B
-7.37%-4.40%-2.54%-43.87% 209B
-0.64%+2.43%+30.52%+64.49% 208B
-0.82%+0.70%+15.96%+71.01% 162B
Average -1.38%-1.20%+30.11%+49.75% 397.08B
Weighted average by Cap. -0.99%-1.93%+39.24%+72.95%

Financials

2026 *2027 *
Net sales 106M 122M 98.94M 90.84M 172M 11.67B 174M 1.17B 458M 5.81B 459M 449M 19.49B 176M 202M 164M 150M 284M 19.33B 288M 1.93B 758M 9.62B 760M 744M 32.26B
Net income 1.27M 1.47M 1.19M 1.09M 2.06M 140M 2.09M 13.98M 5.49M 69.68M 5.51M 5.39M 234M 49.6M 57.06M 46.17M 42.39M 80.05M 5.45B 81.29M 544M 214M 2.71B 214M 210M 9.09B
Net Debt -28.5M -32.78M -26.53M -24.35M -45.99M -3.13B -46.7M -313M -123M -1.56B -123M -120M -5.22B -28.81M -33.14M -26.81M -24.62M -46.49M -3.16B -47.21M -316M -124M -1.57B -124M -122M -5.28B
Logo Cosmo Pharmaceuticals S.p.A
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-